Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...

John "Chip" Scarlett, who as chairman, president and CEO repositioned Geron Corp. and guided the company to its first drug ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

The acquisition of Reata Pharmaceuticals in September 2023 added ... Zurzuvae’s launch also exceeded the company’s internal expectations. However, the new drugs are not generating enough ...

At last week's JPMorgan conference, Biogen chief executive Chris Viehbacher said the company is open to additional bolt-on acquisitions, like its 2023 purchase of Reata Pharma and its rare disease ...

The company has also named biopharma industry veteran Rajiv Patni, formerly R&D head at Reata Pharma ahead of its acquisition by Biogen, as its chief executive. The Series A was co-led by Atlas ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...

Meanwhile, the company's Q4 topline expanded only ... added from its $7.3B acquisition of Reata Pharmaceuticals last year, brought $102.2M in revenue. Zurzuvae, a depression therapy Biogen ...

Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...

Bankrupt drugmaker Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step towards finalizing a proposed opioid ...